NTSB Releases Preliminary Report on Union Pacific Derailment in Kansas
The National Transportation Safety Board (NTSB) issued a preliminary report regarding a Union Pacific train derailment that occurred near Greensburg, Kansas, on October 15, 2026.
Stocks · News reference
Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail
Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next sector by a margin several times wider than any other gap in the table.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
AMZNAVGOCATDIAEOGGEIWMJNJMCDMRKNKENVDAORCLPEPPGQQQSLBSPYUNHUNPWMTXLBXLCXLEXLFXLIXLKXLPXLREXLUXLVXLYXOM
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Court Grants Class Certification in Amazon Photos Biometric Privacy Lawsuit
A U.S. District Court judge has certified a class action lawsuit alleging that Amazon violated Illinois' Biometric Information Privacy Act through its Amazon Photos service.
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
Johnson & Johnson is positioned to achieve double-digit sales growth by 2030 following its consumer health spinoff. Despite facing a major patent cliff with Stelara losing exclusivity in 2025, the company's new drug launches (Icotyde, Inlexzo, Lazcluze, Imaavy) with peak sales potential exceeding $5 billion each, combined with its robotic surgery device Ottava and strong dividend history as a Dividend King, make it an attractive investment for long-term income seekers.
BofA Securities Raises Walmart Price Target to $139
BofA Securities increased its price target for Walmart to $139 from $126 while maintaining a Buy rating, citing expectations for continued market share gains.
Amazon and Microsoft Lead the Cloud Market. One of Them Has Far Greater Upside.
Both Amazon and Microsoft dominate cloud computing with strong growth in AWS and Azure respectively. However, Amazon has greater upside potential due to its more established custom chip business, which has become a $20 billion run-rate business with 20-fold increases in commitments. Amazon's chip advantage provides cost savings and better returns than GPUs, positioning it ahead of Microsoft whose custom chip efforts are still in early stages.